Effect of 1 mg/day finasteride on concentrations of serum prostate-specific antigen in men with androgenic alopecia: a randomised controlled trial

被引:62
作者
D'Amico, Anthony V.
Roehrborn, Claus G.
机构
[1] Brigham & Womens Hosp, Dept Radiat Oncol, Boston, MA 02215 USA
[2] Dana Farber Canc Inst, Boston, MA 02115 USA
[3] Univ Texas, SW Med Ctr, Dept Urol, Dallas, TX USA
关键词
D O I
10.1016/S1470-2045(06)70981-0
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background Use of 5 mg/day finasteride (Proscar) for benign prostatic hyperplasia is known to affect serum concentrations of prostate-specific antigen (PSA). When men taking this treatment undergo screening for prostate cancer, a compensatory adjustment of the PSA concentration (to multiply the value by two) is recommended. Whether this recommendation should apply to men taking 1 mg/day finasteride (Propecia) for the treatment of androgenic alopecia is unknown. We aimed to assess the effect of 1 mg/day finasteride on serum PSA in men aged 40-60 years with male-pattern hair loss. Methods Between March 13, 1998, and Jan 12, 2000, 355 men aged 40-60 years with male-pattern hair loss were stratified by age decade (40-49 years and 50-60 years), and randomised in a ratio of four to one to 1 mg/day finasteride or placebo. The primary endpoint was the effect of this treatment for 48 weeks on serum PSA concentration compared with placebo. This trial is in the process of being registered on the US National Institutes of Health website http://www.clinicaltrials.gov/ct/show/NCT00396175. Analyses were according to protocol. Findings Within 48 weeks of randomisation, men aged 40-49 years and 50-60 years who were assigned 1 mg/day finasteride had a median decrease in serum PSA concentration of 40% (95% CI 34-46) and 50% (44-57), respectively. In men assigned placebo, the median changes were 0% [-14 to 14] and a median increase of 13% [2 to 24], respectively. Interpretation In men aged 40-60 years, 1 mg/day finasteride for 48 weeks lowers serum PSA concentration. Therefore, the existing recommendation for the adjustment of serum PSA concentration in prostate-cancer screening in men taking 5 mg/day finasteride should also apply to men taking the 1 mg/day preparation for male-pattern hair loss. Research is needed to assess the effect of 1 mg/day finasteride preparation beyond 48 weeks of treatment.
引用
收藏
页码:21 / 25
页数:5
相关论文
共 15 条
  • [1] The Prostate, Lung, Colon, and Ovarian (PLCO) cancer screening trial: status and promise
    Andriole, GL
    Reding, D
    Hayes, RB
    Prorok, PC
    Gohagan, JK
    [J]. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2004, 22 (04) : 358 - 361
  • [2] Prostate cancer prevention and finasteride
    D'Amico, Anthony V.
    Barry, Michael J.
    [J]. JOURNAL OF UROLOGY, 2006, 176 (05) : 2010 - 2012
  • [3] DAMICO AV, 2006, 2006 ANN M AM UR ASS
  • [4] Prostate cancer mortality reduction by screening:: Power and time frame with complete enrollment in the European Randomised Screening for Prostate Cancer (ERSPC) trial
    de Koning, HJ
    Liem, MK
    Baan, CA
    Boer, R
    Schröder, FH
    Alexander, FE
    [J]. INTERNATIONAL JOURNAL OF CANCER, 2002, 98 (02) : 268 - 273
  • [5] Long-term effects of finasteride on prostate specific antigen levels: Results from the Prostate Cancer Prevention Trial
    Etzioni, RD
    Howlader, N
    Shaw, PA
    Ankerst, DP
    Penson, DF
    Goodman, PJ
    Thompson, IM
    [J]. JOURNAL OF UROLOGY, 2005, 174 (03) : 877 - 881
  • [6] GRUBB RL, 2006, ANN M AM UR ASS ATL
  • [7] GUESS HA, 1993, UROL CLIN N AM, V20, P627
  • [8] Finasteride in the treatment of men with androgenetic alopecia
    Kaufman, KD
    Olsen, EA
    Whiting, D
    Savin, R
    DeVillez, R
    Bergfeld, W
    Price, VH
    Van Neste, D
    Roberts, JL
    Hordinsky, M
    Shapiro, J
    Binkowitz, B
    Gormley, GJ
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1998, 39 (04) : 578 - 589
  • [9] Evidence for a biopsy derived grade artifact among larger prostate glands
    Kulkarni, GS
    Al-Azab, R
    Lockwood, G
    Toi, A
    Evans, A
    Trachtenberg, J
    Jewett, MAS
    Finelli, A
    Fleshner, NE
    [J]. JOURNAL OF UROLOGY, 2006, 175 (02) : 505 - 509
  • [10] The interpretation of serum prostate specific antigen in men receiving 5α-reductase inhibitors:: A review and clinical recommendations
    Marks, Leonard S.
    Andriole, Gerald L.
    Fitzpatrick, John M.
    Schulman, Claude C.
    Roehrborn, Claus G.
    [J]. JOURNAL OF UROLOGY, 2006, 176 (03) : 868 - 874